Intrinsic value of Castlight Health Cl B - CSLT

Previous Close

$5.40

  Intrinsic Value

$0.13

stock screener

  Rating & Target

str. sell

-98%

Previous close

$5.40

 
Intrinsic value

$0.13

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of CSLT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  29.20
  26.78
  24.60
  22.64
  20.88
  19.29
  17.86
  16.57
  15.42
  14.38
  13.44
  12.59
  11.83
  11.15
  10.54
  9.98
  9.48
  9.04
  8.63
  8.27
  7.94
  7.65
  7.38
  7.14
  6.93
  6.74
  6.56
  6.41
  6.27
  6.14
Revenue, $m
  169
  215
  267
  328
  396
  473
  557
  650
  750
  858
  973
  1,095
  1,225
  1,362
  1,505
  1,655
  1,812
  1,976
  2,147
  2,324
  2,509
  2,701
  2,900
  3,107
  3,322
  3,546
  3,779
  4,021
  4,273
  4,536
Variable operating expenses, $m
  180
  225
  277
  337
  405
  481
  565
  657
  757
  864
  967
  1,089
  1,218
  1,354
  1,497
  1,646
  1,802
  1,965
  2,135
  2,311
  2,495
  2,686
  2,884
  3,090
  3,304
  3,527
  3,758
  3,999
  4,250
  4,511
Fixed operating expenses, $m
  53
  54
  56
  57
  58
  59
  61
  62
  63
  65
  66
  68
  69
  71
  72
  74
  75
  77
  79
  80
  82
  84
  86
  88
  90
  92
  94
  96
  98
  100
Total operating expenses, $m
  233
  279
  333
  394
  463
  540
  626
  719
  820
  929
  1,033
  1,157
  1,287
  1,425
  1,569
  1,720
  1,877
  2,042
  2,214
  2,391
  2,577
  2,770
  2,970
  3,178
  3,394
  3,619
  3,852
  4,095
  4,348
  4,611
Operating income, $m
  -63
  -64
  -65
  -66
  -67
  -68
  -69
  -70
  -70
  -71
  -61
  -61
  -62
  -63
  -64
  -65
  -65
  -66
  -67
  -68
  -68
  -69
  -70
  -71
  -71
  -72
  -73
  -74
  -74
  -75
EBITDA, $m
  -44
  -43
  -42
  -40
  -37
  -35
  -32
  -28
  -24
  -20
  -15
  -10
  -5
  0
  6
  13
  19
  26
  33
  41
  49
  57
  65
  74
  83
  93
  103
  114
  125
  136
Interest expense (income), $m
  0
  0
  1
  3
  4
  6
  8
  11
  13
  16
  19
  22
  26
  30
  34
  38
  42
  47
  51
  56
  62
  67
  73
  78
  84
  91
  97
  104
  111
  119
  126
Earnings before tax, $m
  -64
  -66
  -68
  -71
  -73
  -76
  -79
  -83
  -86
  -90
  -83
  -87
  -92
  -97
  -101
  -107
  -112
  -117
  -123
  -129
  -135
  -142
  -148
  -155
  -162
  -169
  -177
  -185
  -193
  -201
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -64
  -66
  -68
  -71
  -73
  -76
  -79
  -83
  -86
  -90
  -83
  -87
  -92
  -97
  -101
  -107
  -112
  -117
  -123
  -129
  -135
  -142
  -148
  -155
  -162
  -169
  -177
  -185
  -193
  -201

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  279
  354
  440
  540
  653
  779
  918
  1,070
  1,235
  1,413
  1,603
  1,805
  2,018
  2,243
  2,479
  2,727
  2,986
  3,255
  3,536
  3,829
  4,133
  4,449
  4,777
  5,119
  5,474
  5,842
  6,226
  6,625
  7,040
  7,472
Adjusted assets (=assets-cash), $m
  279
  354
  440
  540
  653
  779
  918
  1,070
  1,235
  1,413
  1,603
  1,805
  2,018
  2,243
  2,479
  2,727
  2,986
  3,255
  3,536
  3,829
  4,133
  4,449
  4,777
  5,119
  5,474
  5,842
  6,226
  6,625
  7,040
  7,472
Revenue / Adjusted assets
  0.606
  0.607
  0.607
  0.607
  0.606
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
Average production assets, $m
  79
  100
  125
  153
  185
  220
  260
  303
  349
  400
  453
  510
  571
  634
  701
  771
  845
  921
  1,000
  1,083
  1,169
  1,258
  1,351
  1,448
  1,548
  1,653
  1,761
  1,874
  1,991
  2,114
Working capital, $m
  -5
  -6
  -8
  -10
  -12
  -14
  -17
  -19
  -22
  -26
  -29
  -33
  -37
  -41
  -45
  -50
  -54
  -59
  -64
  -70
  -75
  -81
  -87
  -93
  -100
  -106
  -113
  -121
  -128
  -136
Total debt, $m
  26
  52
  81
  115
  154
  197
  245
  297
  353
  414
  479
  548
  621
  698
  779
  863
  952
  1,044
  1,140
  1,240
  1,344
  1,452
  1,565
  1,681
  1,803
  1,929
  2,060
  2,196
  2,338
  2,486
Total liabilities, $m
  95
  121
  151
  185
  223
  266
  314
  366
  422
  483
  548
  617
  690
  767
  848
  933
  1,021
  1,113
  1,209
  1,309
  1,413
  1,522
  1,634
  1,751
  1,872
  1,998
  2,129
  2,266
  2,408
  2,555
Total equity, $m
  183
  233
  290
  355
  430
  513
  604
  704
  813
  930
  1,055
  1,187
  1,328
  1,476
  1,631
  1,794
  1,965
  2,142
  2,327
  2,519
  2,719
  2,927
  3,144
  3,368
  3,602
  3,844
  4,097
  4,359
  4,632
  4,917
Total liabilities and equity, $m
  278
  354
  441
  540
  653
  779
  918
  1,070
  1,235
  1,413
  1,603
  1,804
  2,018
  2,243
  2,479
  2,727
  2,986
  3,255
  3,536
  3,828
  4,132
  4,449
  4,778
  5,119
  5,474
  5,842
  6,226
  6,625
  7,040
  7,472
Debt-to-equity ratio
  0.140
  0.220
  0.280
  0.320
  0.360
  0.380
  0.400
  0.420
  0.430
  0.450
  0.450
  0.460
  0.470
  0.470
  0.480
  0.480
  0.480
  0.490
  0.490
  0.490
  0.490
  0.500
  0.500
  0.500
  0.500
  0.500
  0.500
  0.500
  0.500
  0.510
Adjusted equity ratio
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658
  0.658

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -64
  -66
  -68
  -71
  -73
  -76
  -79
  -83
  -86
  -90
  -83
  -87
  -92
  -97
  -101
  -107
  -112
  -117
  -123
  -129
  -135
  -142
  -148
  -155
  -162
  -169
  -177
  -185
  -193
  -201
Depreciation, amort., depletion, $m
  19
  21
  24
  26
  30
  33
  37
  41
  46
  51
  45
  51
  57
  63
  70
  77
  84
  92
  100
  108
  117
  126
  135
  145
  155
  165
  176
  187
  199
  211
Funds from operations, $m
  -45
  -45
  -44
  -44
  -44
  -43
  -42
  -41
  -40
  -39
  -38
  -36
  -35
  -33
  -31
  -29
  -27
  -25
  -23
  -21
  -18
  -16
  -13
  -10
  -7
  -4
  -1
  3
  6
  10
Change in working capital, $m
  -1
  -1
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
Cash from operations, $m
  -43
  -43
  -43
  -42
  -42
  -41
  -40
  -38
  -37
  -36
  -34
  -33
  -31
  -29
  -27
  -25
  -23
  -20
  -18
  -16
  -13
  -10
  -7
  -4
  -1
  3
  6
  10
  14
  18
Maintenance CAPEX, $m
  -6
  -8
  -10
  -12
  -15
  -18
  -22
  -26
  -30
  -35
  -40
  -45
  -51
  -57
  -63
  -70
  -77
  -84
  -92
  -100
  -108
  -117
  -126
  -135
  -145
  -155
  -165
  -176
  -187
  -199
New CAPEX, $m
  -18
  -21
  -25
  -28
  -32
  -36
  -39
  -43
  -47
  -50
  -54
  -57
  -60
  -64
  -67
  -70
  -73
  -76
  -79
  -83
  -86
  -89
  -93
  -97
  -100
  -104
  -108
  -113
  -117
  -122
Cash from investing activities, $m
  -24
  -29
  -35
  -40
  -47
  -54
  -61
  -69
  -77
  -85
  -94
  -102
  -111
  -121
  -130
  -140
  -150
  -160
  -171
  -183
  -194
  -206
  -219
  -232
  -245
  -259
  -273
  -289
  -304
  -321
Free cash flow, $m
  -67
  -72
  -77
  -83
  -89
  -95
  -101
  -107
  -114
  -121
  -128
  -135
  -142
  -150
  -157
  -165
  -173
  -181
  -190
  -198
  -207
  -216
  -226
  -236
  -246
  -257
  -268
  -279
  -291
  -303
Issuance/(repayment) of debt, $m
  21
  26
  30
  34
  39
  43
  48
  52
  56
  61
  65
  69
  73
  77
  81
  85
  88
  92
  96
  100
  104
  108
  112
  117
  121
  126
  131
  136
  142
  148
Issuance/(repurchase) of shares, $m
  105
  115
  125
  136
  147
  159
  171
  183
  195
  207
  208
  220
  232
  245
  257
  269
  282
  295
  308
  322
  335
  350
  364
  380
  396
  412
  429
  447
  466
  486
Cash from financing (excl. dividends), $m  
  126
  141
  155
  170
  186
  202
  219
  235
  251
  268
  273
  289
  305
  322
  338
  354
  370
  387
  404
  422
  439
  458
  476
  497
  517
  538
  560
  583
  608
  634
Total cash flow (excl. dividends), $m
  59
  68
  78
  87
  97
  107
  117
  127
  137
  147
  145
  154
  163
  172
  180
  189
  198
  206
  215
  223
  232
  241
  251
  261
  271
  282
  293
  305
  317
  330
Retained Cash Flow (-), $m
  -105
  -115
  -125
  -136
  -147
  -159
  -171
  -183
  -195
  -207
  -208
  -220
  -232
  -245
  -257
  -269
  -282
  -295
  -308
  -322
  -335
  -350
  -364
  -380
  -396
  -412
  -429
  -447
  -466
  -486
Prev. year cash balance distribution, $m
  33
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  24
  32
  40
  50
  61
  74
  88
  104
  121
  140
  160
  182
  205
  229
  255
  281
  310
  339
  370
  401
  435
  469
  505
  542
  581
  621
  663
  707
  752
  799
Cash available for distribution, $m
  -13
  -47
  -48
  -49
  -50
  -52
  -53
  -55
  -58
  -60
  -63
  -66
  -69
  -73
  -77
  -80
  -85
  -89
  -94
  -98
  -103
  -108
  -114
  -119
  -125
  -130
  -136
  -143
  -149
  -156
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -13
  -43
  -41
  -40
  -39
  -37
  -36
  -35
  -33
  -32
  -30
  -28
  -26
  -24
  -22
  -20
  -18
  -16
  -14
  -12
  -11
  -9
  -7
  -6
  -5
  -4
  -3
  -2
  -2
  -1
Current shareholders' claim on cash, %
  84.0
  72.4
  63.6
  56.7
  51.2
  46.8
  43.1
  40.0
  37.3
  35.0
  33.1
  31.4
  29.9
  28.6
  27.4
  26.2
  25.2
  24.3
  23.4
  22.6
  21.9
  21.2
  20.5
  19.9
  19.3
  18.8
  18.2
  17.7
  17.3
  16.8

Castlight Health, Inc. offers a health benefits platform that engages employees to make healthcare decisions, and enables employers to communicate and measure their benefit programs. The Company operates through cloud-based products segment. Its technology offering aggregates data and applies analytics to make healthcare data transparent. Its products deliver employee engagement and enable employers to integrate benefit programs into a single platform available to employees and their families. Its health benefits platform engages external data and its substantial user base to provide a single, end-to-end solution that engages employees through personalized and relevant communications. Its offering provides employers the opportunity to communicate, measure, and get value out of their benefits and programs on a real-time basis. It offers cross-sell products, such as Castlight Action, Castlight Pharmacy, Castlight Dental, Castlight Elevate, Castlight Protect and Castlight Rewards.

FINANCIAL RATIOS  of  Castlight Health Cl B (CSLT)

Valuation Ratios
P/E Ratio -9.5
Price to Sales 5.5
Price to Book 5.5
Price to Tangible Book
Price to Cash Flow -15.2
Price to Free Cash Flow -14.4
Growth Rates
Sales Growth Rate 36%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -60%
Cap. Spend. - 3 Yr. Gr. Rate -7.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -35.8%
Ret/ On Assets - 3 Yr. Avg. -44.1%
Return On Total Capital -53.6%
Ret/ On T. Cap. - 3 Yr. Avg. -60.7%
Return On Equity -53.6%
Return On Equity - 3 Yr. Avg. -60.7%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 65.7%
Gross Margin - 3 Yr. Avg. 53.6%
EBITDA Margin -54.9%
EBITDA Margin - 3 Yr. Avg. -114.6%
Operating Margin -57.8%
Oper. Margin - 3 Yr. Avg. -117.6%
Pre-Tax Margin -57.8%
Pre-Tax Margin - 3 Yr. Avg. -117.2%
Net Profit Margin -57.8%
Net Profit Margin - 3 Yr. Avg. -117.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CSLT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CSLT stock intrinsic value calculation we used $131 million for the last fiscal year's total revenue generated by Castlight Health Cl B. The default revenue input number comes from 2017 income statement of Castlight Health Cl B. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CSLT stock valuation model: a) initial revenue growth rate of 29.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CSLT is calculated based on our internal credit rating of Castlight Health Cl B, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Castlight Health Cl B.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CSLT stock the variable cost ratio is equal to 108%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $52 million in the base year in the intrinsic value calculation for CSLT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Castlight Health Cl B.

Corporate tax rate of 27% is the nominal tax rate for Castlight Health Cl B. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CSLT stock is equal to 18.7%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CSLT are equal to 46.6%.

Life of production assets of 10 years is the average useful life of capital assets used in Castlight Health Cl B operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CSLT is equal to -3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $175 million for Castlight Health Cl B - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 126 million for Castlight Health Cl B is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Castlight Health Cl B at the current share price and the inputted number of shares is $0.7 billion.

RELATED COMPANIES Price Int.Val. Rating
BNFT Benefitfocus 38.00 2.96  str.sell
ANTM Anthem 248.52 389.02  str.buy
CSOD Cornerstone On 53.59 7.26  str.sell
ULTI Ultimate Softw 292.05 72.93  str.sell
PCTY Paylocity Hold 64.90 126.54  str.buy
PAYC Paycom Softwar 111.76 184.84  str.buy
ADBE Adobe Systems 257.54 199.05  hold
NH NantHealth 3.07 0.02  str.sell

COMPANY NEWS

▶ Castlight Health to Announce Second Quarter 2018 Results   [Jul-12-18 08:00AM  PR Newswire]
▶ Castlight Announces Return on Investment Guarantee   [Jul-11-18 06:00AM  PR Newswire]
▶ Castlight: 1Q Earnings Snapshot   [May-10-18 06:17PM  Associated Press]
▶ Castlight Health to Announce First Quarter 2018 Results   [Apr-11-18 08:00AM  PR Newswire]
▶ Castlight reports 4Q loss   [Feb-21-18 07:59PM  Associated Press]
▶ Castlight Health to Announce Fourth Quarter 2017 Results   [Jan-25-18 08:00AM  PR Newswire]
▶ Castlight reports 3Q loss   [Oct-25-17 07:45PM  Associated Press]
▶ Castlight Health to Announce Third Quarter 2017 Results   [Oct-05-17 08:00AM  PR Newswire]
▶ [$$] GE Cuts Wind-Energy Stock Stake by $30M   [Aug-16-17 05:52AM  Barrons.com]
▶ Castlight reports 2Q loss   [Aug-04-17 03:11AM  Associated Press]
▶ Castlight Health Announces Second Quarter 2017 Results   [Aug-02-17 04:20PM  PR Newswire]
▶ Castlight Health to Announce Second Quarter 2017 Results   [Jul-13-17 08:00AM  PR Newswire]
▶ 3 Digital Health Companies Poised for Sizzling Growth   [May-16-17 03:02PM  Motley Fool]
▶ What's Behind Castlight Health Rallying 13.2% Today   [May-10-17 04:57PM  Motley Fool]
▶ Castlight reports 1Q loss   [Apr-26-17 07:02PM  Associated Press]
▶ Castlight Health completes acquisition of startup Jiff   [Apr-05-17 10:53AM  American City Business Journals]
▶ Here's Why Castlight Health Inc. Is Soaring Today   [Feb-16-17 02:15PM  at Motley Fool]
▶ Castlight reports 4Q loss   [06:38PM  AP]
▶ 13 Questions For Bryan Roberts Of Venrock   [Jan-31-17 08:33AM  at Forbes]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.